Compare VINP & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VINP | MRVI |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.7M | 559.0M |
| IPO Year | 2020 | 2020 |
| Metric | VINP | MRVI |
|---|---|---|
| Price | $9.54 | $5.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $14.00 | $4.13 |
| AVG Volume (30 Days) | 68.0K | ★ 2.7M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $18.07 | $12.54 |
| Revenue Next Year | $12.74 | $7.87 |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.20 | $1.99 |
| 52 Week High | $13.61 | $5.21 |
| Indicator | VINP | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 31.85 | 71.47 |
| Support Level | N/A | $3.27 |
| Resistance Level | $10.24 | N/A |
| Average True Range (ATR) | 0.31 | 0.24 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 9.59 | 86.78 |
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.